Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): An emerging cause of multidrug-resistant infection

Keyphrases

• Treatment Options 100%
• Klebsiella Pneumoniae Carbapenemase 100%
• Multidrug-resistant Infection 100%
• Infection Treatment 42%
• Optimal Treatment 28%
• Carbapenems 28%
• Clinical Outcomes 28%
• Combination Therapy 14%
• Monotherapy 14%
• Clinical Data 14%
• Antimicrobial 14%
• Lactams 14%
• Bacterial Isolates 14%
• Automated System 14%
• Phenotypic Methods 14%
• Cephalosporins 14%
• Positive Outcomes 14%
• Controlled Experiment 14%
• Aminoglycosides 14%
• Clinical Microbiology Laboratory 14%
• Penicillin 14%
• Polymyxin 14%
• Gram-negative Infections 14%
• Boronic Acid 14%
• Clinical Success Rate 14%
• Confirmatory Test 14%
• Last Resort 14%
• Tigecycline 14%
• Monobactam 14%
• Disk Test 14%
• Carbapenemases 14%
• Number of Patients 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Infection 100%
• Klebsiella pneumoniae 100%
• Carbapenemase 100%
• Carbapenem Derivative 25%
• Controlled Clinical Trial 12%
• Lactam 12%
• Antiinfective Agent 12%
• Gram Negative Infection 12%
• Penicillin Derivative 12%
• Cephalosporin Derivative 12%
• Polymyxin 12%
• Boronic Acid Derivative 12%
• Monobactam Derivative 12%
• Combination Therapy 12%
• Monotherapy 12%
• Aminoglycoside 12%
• Tigecycline 12%

Immunology and Microbiology

• Klebsiella pneumoniae 100%
• Clinical Microbiology 14%
• Penicillin 14%
• Polymyxin 14%